[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

[PRESSWIRE] London, UK - 14.04.22 -- Zero Carbon Capital Ltd has today announced the first close of the new Zero Carbon Capital 2022 LP fund. They have raised £10m toward a target of £30m to invest in extraordinary early-stage European companies building innovative, scientific solutions to the biggest, hardest challenges of decarbonisation.

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

[PRESSWIRE] Vienna - 03 February, 2022 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.

• Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants
• Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening
• A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

[PRESSWIRE] Vienna -- 17th August 2021 - CEBINA GmbH, Central European Biotech Incubator and Accelerator today announces the publication of the first results of a Phase 2 efficacy clinical trial sponsored jointly with its partner URSAPHARM Arzneimittel GmbH demonstrating that a nasal spray containing the active ingredient azelastine was effective in accelerating the reduction of the viral load in SARS-CoV-2 positive patients. Azelastine has been marketed in an identical composition by URSAPHARM for many years and is used as an antiallergic.

[PRESSWIRE] 03 August, 2021 -- In the 1940s Albert Szent-Györgyi - a Nobel-prize winning Hungarian biochemist known for his work in science - wrote that “the future will be, like the schools are today”. In 2021, these words still ring true, even more so for the winners of the European Code League competition, Dr Corina Toma, Mihaela Giurgea and their students from Tiberiu Popoviciu High School of Computer Science in Romania. The second and third places went to teams from Turkey and Greece.

• Carbon Engineering and BeZero Carbon join forces to offer a new retail option for customers seeking to address their carbon footprint through Direct Air Capture technology.
• BeZero’s Carbon Rating Framework gives customers an additional tool to assess the quality of available solutions, with Direct Air Capture the only AAA+ top-rated solution.

Frodeno is renowned as one of the greatest triathletes of his generation. The Olympic gold medalist will use the Supersapiens system to effectively manage his fueling strategy to continue in his pursuit of earning another Ironman World Championship title.